DK3494960T3 - Stabiliserede sammensætninger af alkyleringsmidler og fremgangsmåder til anvendelse af samme - Google Patents

Stabiliserede sammensætninger af alkyleringsmidler og fremgangsmåder til anvendelse af samme Download PDF

Info

Publication number
DK3494960T3
DK3494960T3 DK18214529.2T DK18214529T DK3494960T3 DK 3494960 T3 DK3494960 T3 DK 3494960T3 DK 18214529 T DK18214529 T DK 18214529T DK 3494960 T3 DK3494960 T3 DK 3494960T3
Authority
DK
Denmark
Prior art keywords
alkyling
procedures
agents
same
stabilized compositions
Prior art date
Application number
DK18214529.2T
Other languages
English (en)
Inventor
Robert Alonso
Barry R Walker
Peter A Crooks
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Application granted granted Critical
Publication of DK3494960T3 publication Critical patent/DK3494960T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK18214529.2T 2008-03-27 2009-03-11 Stabiliserede sammensætninger af alkyleringsmidler og fremgangsmåder til anvendelse af samme DK3494960T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3984008P 2008-03-27 2008-03-27
EP09724939.5A EP2273876B1 (en) 2008-03-27 2009-03-11 Stabilized compositions of alkylating agents and methods of using same

Publications (1)

Publication Number Publication Date
DK3494960T3 true DK3494960T3 (da) 2021-01-25

Family

ID=41114573

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18214529.2T DK3494960T3 (da) 2008-03-27 2009-03-11 Stabiliserede sammensætninger af alkyleringsmidler og fremgangsmåder til anvendelse af samme

Country Status (14)

Country Link
US (2) US8501817B2 (da)
EP (2) EP3494960B1 (da)
CN (2) CN107149591A (da)
CY (2) CY1121777T1 (da)
DK (1) DK3494960T3 (da)
ES (2) ES2727523T3 (da)
HR (2) HRP20190551T1 (da)
HU (2) HUE043767T2 (da)
LT (2) LT3494960T (da)
PL (2) PL2273876T3 (da)
PT (2) PT2273876T (da)
SI (2) SI3494960T1 (da)
TR (1) TR201907794T4 (da)
WO (1) WO2009120493A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
SI3494960T1 (sl) 2008-03-27 2021-04-30 Helsinn Healthcare Sa Stabilizirani sestavki alkilirajočih sredstev in metode uporabe le-teh
US20180125797A1 (en) * 2016-11-07 2018-05-10 Actelion Pharmaceuticals Ltd Methods for treating skin disorders with a topical composition of bis-(2-chloroethyl)methylamine

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4083692A (en) 1970-06-04 1978-04-11 The United States Of America As Represented By The Secretary Of The Army Detection and estimation of microquantities of alkylating agents
US3767792A (en) 1971-07-02 1973-10-23 Stanley Drug Products Inc Method for controlling the toxicity of drug products
US3904766A (en) 1973-06-19 1975-09-09 Scott Eugene J Van Treatment of psoriasis
US4206222A (en) * 1977-06-23 1980-06-03 Societe Civile Particuliere De Brevets Suffren Method for preparing a substance having properties against collagen diseases and products obtained
WO1987004154A1 (en) 1986-01-03 1987-07-16 The University Of Melbourne Melphalan derivatives
US4863910A (en) 1986-05-20 1989-09-05 Takeo Takayanagi Complexes of AZO compounds and/or their salts and an antitumor agent and a method for reducing the growth of tumors
US4725438A (en) * 1986-05-29 1988-02-16 Leazer Billie S Aloe vera ointment
IE60588B1 (en) * 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
US5326790A (en) 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
US4853388A (en) 1987-05-15 1989-08-01 Pearlman Dale L Method for treating psoriasis with cytotoxic agents
US5051363A (en) 1987-06-26 1991-09-24 University Of Pennsylvania Method for modifying the toxicity of DNA reactive cross-linking agents to cells
US5229422A (en) 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
GB8727157D0 (en) 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4949641A (en) 1990-03-05 1990-08-21 The United States Of America As Represented By The Secretary Of The Army Method of safely detoxifying mustard gases
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5820872A (en) 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
EP0716589A4 (en) * 1993-07-23 1997-06-11 Morris Herstein COSMETIC COMPOSITION STIMULATING THE RENEWAL OF THE SKIN WITH A PROLONGED IRRITATION ELIMINATION EFFECT
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
GB9501052D0 (en) * 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
US6551611B2 (en) * 1995-09-28 2003-04-22 Schering Aktiengesellschaft Hormone replacement therapy method
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6124108A (en) 1996-05-15 2000-09-26 The United States Of America As Represented By The Secretary Of The Army Protein biomarker for mustard chemical injury
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
ATE326238T1 (de) 1996-06-27 2006-06-15 Chugai Pharmaceutical Co Ltd Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann
EP1024833A1 (en) * 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6753155B1 (en) 1997-05-13 2004-06-22 The United States Of America As Represented By The Secretary Of The Army Protein biomarker for mustard chemical injury
EP1019034A2 (en) * 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
AU760252B2 (en) * 1998-01-30 2003-05-08 Cold Spring Harbor Laboratory Modulation of cell proliferation, methods and reagents
GB9805868D0 (en) 1998-03-20 1998-05-13 Zeneca Ltd Anti-tumour agents
US6399678B2 (en) * 1998-06-25 2002-06-04 Tamko Roofing Products Silicone-aggregate mixtures for pumping and spraying applications
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6329148B1 (en) * 1999-02-16 2001-12-11 The Board Of Trustees Of The Leland Stanford University Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
US6017902A (en) 1999-02-25 2000-01-25 Brookhaven Science Associates Boron containing amino acid compounds and methods for their use
US20020146692A1 (en) 2000-01-21 2002-10-10 Victoria Yamazaki Methods and materials relating to G protein-coupled receptor-like polypeptides and polynucleotides
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20030215471A1 (en) * 2001-01-31 2003-11-20 Wilmott James M. Surfactant free topical compositions and method for rapid preparation thereof
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
WO2003094954A1 (en) 2001-09-25 2003-11-20 Quick Med Technologies, Inc. Composition and method for minimizing or avoiding adverse effects of vesicants
US20030082229A1 (en) 2001-11-01 2003-05-01 Board Of Regents, The University Of Texas Systems Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
CA2504665C (en) * 2002-11-12 2012-12-18 Jewish General Hospital Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
US8088605B2 (en) 2002-12-04 2012-01-03 Technologies Biolactics Inc. Exopolysaccharides delivery system for active molecules
US20050039228A1 (en) 2003-06-19 2005-02-17 The Samuel Roberts Noble Foundation Methods and compositions for analysis of plant gene function
WO2005007129A2 (en) 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
US20070287719A1 (en) * 2005-03-11 2007-12-13 Pfizer Inc Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US20060281720A1 (en) * 2005-06-08 2006-12-14 Loria Roger M 5-Androstenediol As An Inhibitor of Gliomas
SI3494960T1 (sl) * 2008-03-27 2021-04-30 Helsinn Healthcare Sa Stabilizirani sestavki alkilirajočih sredstev in metode uporabe le-teh

Also Published As

Publication number Publication date
PT3494960T (pt) 2021-02-09
CN107149591A (zh) 2017-09-12
CY1121777T1 (el) 2020-07-31
CY1123974T1 (el) 2022-05-27
WO2009120493A2 (en) 2009-10-01
TR201907794T4 (tr) 2019-06-21
PL3494960T3 (pl) 2021-05-17
ES2727523T3 (es) 2019-10-16
HUE053482T2 (hu) 2021-06-28
US8501817B2 (en) 2013-08-06
LT2273876T (lt) 2019-05-27
ES2848841T3 (es) 2021-08-12
CN102036557A (zh) 2011-04-27
EP2273876A4 (en) 2013-10-23
WO2009120493A3 (en) 2010-03-04
EP3494960B1 (en) 2020-11-25
HRP20210283T1 (hr) 2021-04-02
US20100029783A9 (en) 2010-02-04
SI2273876T1 (sl) 2019-09-30
EP2273876A2 (en) 2011-01-19
EP2273876B1 (en) 2019-03-06
EP3494960A1 (en) 2019-06-12
US20140142193A1 (en) 2014-05-22
US20090247645A1 (en) 2009-10-01
LT3494960T (lt) 2021-02-25
HRP20190551T1 (hr) 2019-05-03
HUE043767T2 (hu) 2019-09-30
SI3494960T1 (sl) 2021-04-30
PL2273876T3 (pl) 2019-09-30
PT2273876T (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
DK2653873T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2181330T3 (da) Sammensætninger og midler til diagnosticering af mikrobielle infektioner
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
DK1858864T3 (da) Stabiliserede sammensætninger af flygtige alkyleringsmidler og fremgangsmåder til anvendelse deraf
DK2046264T3 (da) Fremgangsmåder til fremstillingen af sammensætninger med film
DK2346321T4 (da) Sammensætning til forbedring af effektiviteten af herbicider
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK2068927T3 (da) Fremgangsmåder til reducering af eosinofilniveauer
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK3354276T3 (da) Sammensætninger til behandlingen af gastrointestinal inflammation
DK2470656T3 (da) Sammensætning til hæmning af genekspression og anvendelser heraf
DK2894165T3 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2231565T3 (da) Fremgangsmåder til fremstilling af clorerede carbonhydrider
DK3461503T3 (da) Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
DK2124999T3 (da) Activin-actrii antagonister og anvendelser til behandling af anæmi
DK2131856T3 (da) Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande
DK3081215T3 (da) Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten